Severe disease exacerbations in patients with multiple sclerosis after discontinuing fingolimod

被引：23
作者：
Czlonkowska, Anna [1 ,2 ]
Smolinski, Lukasz [1 ]
Litwin, Tomasz [1 ]
机构：
[1] Inst Psychiat & Neurol, Dept Neurol 2, Ul Sobieskiego 9, PL-02957 Warsaw, Poland
[2] Med Univ Warsaw, Dept Clin & Expt Pharmacol, Warsaw, Poland
来源：
NEUROLOGIA I NEUROCHIRURGIA POLSKA | 2017年 / 51卷 / 02期
关键词：
Multiple sclerosis; Fingolimod; Withdrawal; immune reconstitution inflammatory syndrome; RECONSTITUTION INFLAMMATORY SYNDROME; NATALIZUMAB THERAPY; CESSATION; WITHDRAWAL; FTY720; REACTIVATION; EFFICACY; RELAPSE; RETURN;
D O I：
10.1016/j.pjnns.2017.01.006
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Discontinuation of fingolimod in patients with multiple sclerosis (MS) can lead to disease reactivation. In this review, we describe cases of severe exacerbations in patients with MS following discontinuation of fingolimod, including three cases from our center. We consider potential mechanisms of disease reactivation after cessation of fingolimod, and the evidence supporting this rebound effect. We conclude that discontinuation of fingolimod results in the return of disease activity, which then leads to severe exacerbations (i.e., rebounds) in a clinically significant proportion of patients. Lastly, we consider diseasemodifying treatment options for patients who discontinue fingolimod. (C) 2017 Published by Elsevier Sp. z o. o. on behalf of Polish Neurological Society.
引用
收藏
页码：156 / 162
页数：7
相关论文
共 38 条
  • [1] Alroughani R, 2014, BMJ CASE REP
  • [2] Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica A pilot study
    Araki, Manabu
    Matsuoka, Takako
    Miyamoto, Katsuichi
    Kusunoki, Susumu
    Okamoto, Tomoko
    Murata, Miho
    Miyake, Sachiko
    Aranami, Toshimasa
    Yamamura, Takashi
    [J]. NEUROLOGY, 2014, 82 (15) : 1302 - 1306
  • [3] Rebound exacerbation multiple sclerosis following cessation of oral treatment
    Beran, Roy G.
    Hegazi, Yaser
    Schwartz, Raymond S.
    Cordato, Dennis J.
    [J]. MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2013, 2 (03) : 252 - 255
  • [4] Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation
    Berger, Benjamin
    Baumgartner, Annette
    Rauer, Sebastian
    Mader, Irina
    Luetzen, Niklas
    Farenkopf, Ulrich
    Stich, Oliver
    [J]. JOURNAL OF NEUROIMMUNOLOGY, 2015, 282 : 118 - 122
  • [5] Relapse, rebound, and psoriasis adverse events: An advisory group report
    Carey, W
    Glazer, S
    Gottlieb, AB
    Lebwohl, M
    Leonardi, C
    Menter, A
    Papp, K
    Rundle, AC
    Toth, D
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (04) : S171 - S181
  • [6] Dysregulation of sphingosine 1 phosphate receptor-1 (S1P1) signaling and regulatory lymphocyte-dependent immunosuppression in a model of post-fingorimod MS rebound
    Cavone, Leonardo
    Felici, Roberta
    Lapucci, Andrea
    Buonvicino, Daniela
    Pratesi, Sara
    Muzzi, Mirko
    Hakiki, Bahia
    Maggi, Laura
    Peruzzi, Benedetta
    Caporale, Roberto
    Annunziato, Francesco
    Amato, Maria Pia
    Chiarugi, Alberto
    [J]. BRAIN BEHAVIOR AND IMMUNITY, 2015, 50 : 78 - 86
  • [7] Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis
    Chun, Jerold
    Hartung, Hans-Peter
    [J]. CLINICAL NEUROPHARMACOLOGY, 2010, 33 (02) : 91 - 101
  • [8] Clifford DB, 2010, LANCET NEUROL, V9, P438, DOI 10.1016/S1474-4422(10)70028-4
  • [9] Davion J-B, 2016, J NEUROL
  • [10] Dramatic recovery of steroid-refractory relapsed multiple sclerosis following Fingolimod discontinuation using selective immune adsorption
    De Masi, Roberto
    Accoto, Salvatore
    Orlando, Stefania
    De Blasi, Vincenzo
    Pasca, Sergio
    Scarpello, Rocco
    Spagnolo, Leo
    Idolo, Adele
    De Donno, Antonella
    [J]. BMC NEUROLOGY, 2015, 15
1234